In addition to evaluation of response to BRAF and MEK inhibitors, HTDS identified notable sensitivities to single agent dinaciclib, vorinostat, ganetespib and doxorubicin across multiple BRAF-mutant metastatic melanoma PDXCs. This evidence concerns the gene BRAF and metastatic melanoma.